VISEN Pharmaceuticals
Agent40 out of 100, Below median. Agent Readiness. Open the scores section.Agent Readiness: 40/100. Below median. Measured by StartupHub.ai. Median 41.Trust65 out of 100, Above median. Data Trust. Open the scores section.Data Trust: 65/100. Above median. Measured by StartupHub.ai. Median 61.VISEN Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases.
About
VISEN Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from inflammatory and fibrotic diseases. Their lead drug candidate, VISN-101, is a novel small molecule inhibitor targeting a key pathway implicated in these conditions. The company aims to address significant unmet medical needs in areas like idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders.
Similar companies
Leveraging the adaptive immune system to diagnose and treat disease.
Shares Biotech, HealthTech
A global oncology company developing and commercializing innovative cancer treatments.
Shares Biotech, MedTech
Synthace provides a no-code cloud platform for life sciences R&D, enabling scientists to automate experimentation and insight sharing.
Shares Biotech, MedTech
Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.
Shares Biotech, MedTech
Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.
Shares Biotech, MedTech
Developing engineered biologics to harness the immune system for disease treatment.
Shares Biotech, Drug Discovery
Key facts
- Website
- visenpharma.com
- Headquarters
- San Diego, United States
- Founded
- 2017
- Total funding
- $200M
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 11 Jun 2025 | Undisclosed round | Undisclosed | Reynold Lemkins |
| 1 Jan 2023 | Series B | $50M | Deerfield Management |
| 8 Jan 2021 | Series B | $150M |
Tech stack
Detected on visenpharma.com, last scanned 4 Nov 2026. Run your own scan
- Frontend
- Nuxt, jQuery, Bootstrap
- Email provider
- Self-hosted
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is VISEN Pharmaceuticals trustworthy and reputable?
StartupHub's Data Trust & Reputation score for VISEN Pharmaceuticals is 65 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has VISEN Pharmaceuticals raised?
VISEN Pharmaceuticals has raised a total of $200M in funding.
SEC filings, insider activity, nonprofit links and pay benchmarks for VISEN Pharmaceuticals:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
